Novo Wegovy Pill: 4.1 percent Weight Loss After Injection Switch

Wegovy pill users who switched from injectable obesity treatments lost an average 4.1 percent of their body weight over three months, according to new real-world data from Novo Nordisk's OCTANE study.

The analysis, presented at the European Association for the Study of Diabetes meeting in Milan, involved 194 adults who moved from injectable semaglutide or tirzepatide to oral semaglutide.

The findings add a different dimension to the expanding oral obesity drug market: rather than viewing pills only as an alternative to injections, the data raises the question of whether oral semaglutide could provide a treatment-continuity pathway for patients already using injectable GLP-1 therapies.

What happened after patients switched to the Wegovy pill?

Participants in the OCTANE study lost an average of 4.0 kg from a baseline average weight of 100.5 kg after three months on oral semaglutide.

About 40.7 percent achieved at least 5 percent weight loss, while the share classified as having obesity based on BMI fell from 87.1 percent to 65.5 percent.

The study included people who had previously used injectable semaglutide or tirzepatide, meaning the analysis examined a treatment transition rather than first-time use of a GLP-1 medicine.

The average gap between the last injectable prescription and starting oral semaglutide was 36.8 days.

Also Read: Why Peptides and Complex Generics Will Define India Pharma's Future

Can oral semaglutide become a continuation pathway?

The significance of the findings lies in what they suggest about the next phase of obesity treatment. The debate around oral obesity drugs has largely focused on whether patients will choose tablets instead of injections.

The OCTANE data instead points to another potential use case: patients who have already entered GLP-1 treatment may be able to change formulation while continuing to lose weight.

This could become increasingly relevant as obesity treatment moves toward long-term management. Novo Nordisk is already expanding the Wegovy pill across markets, while Eli Lilly is competing in the oral GLP-1 segment with its own products.

Oral therapies will account for about one-fourth of U.S. obesity prescriptions according to a IQVIA report, highlighting how quickly the formulation mix is changing.

What does the study actually prove?

The results provide real-world evidence, but they do not establish that switching to oral semaglutide directly caused the observed weight loss. OCTANE was a retrospective analysis using telehealth data, including electronic health records, pharmacy records and patient-reported information.

There are also important limitations. Patients had to remain on oral semaglutide for three months and provide weight data, which can introduce selection bias.

The study also had variable data completeness and the findings may not represent the broader population of people using obesity medicines. Novo Nordisk itself states that real-world studies can identify associations but cannot establish causality in the way randomized controlled trials can.

Why could switching matter for the obesity drug market?

The emerging opportunity is therefore broader than convenience. If patients can transition between injectable and oral formulations while maintaining treatment outcomes, pharmaceutical companies could increasingly compete around different stages of the same patient's treatment journey.

For Novo Nordisk, the evidence also arrives as competition with Eli Lilly intensifies in oral obesity medicines.

Novo has captured more than 80 percent of U.S. oral obesity prescriptions following the new Wegovy pill's rollout. The longer-term question will be whether early real-world switching results translate into sustained outcomes across larger and more diverse patient populations.